← All trials
NCT04249544
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vanderbilt UniversityLead sponsor
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.